|
In-licensing has been a core function for Onconome as we continuously seek and evaluate new diagnostic technologies and collaborative prospects with universities and other biotechnology companies.
Our aggressive in-licensing program focuses on novel proteomic and/or genomic biomarkers and biomarker combinations with diagnostic, prognostic, staging and/or response to treatment indications for cancer and other major diseases with unmet diagnostic needs.
We are keen to expand our partnerships with universities and other biotechnology companies to create long-term collaborations that will facilitate development and commercialization of biomarker discoveries.
|
